Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
benzinga.com/general/biotech/25/03/44120928/tevogen-bios-t-cell-therapy-approach-stands-out-analyst-sees-strong-potential
On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a clinical-stage immunotherapy company.
The company’s lead pipeline product, TVGN-489, is a SARS-CoV-2-specific therapy.
Tevogen’s pipeline includes preclinical programs targeting Epstein-Barr…
This story appeared on benzinga.com, 2025-03-04 18:52:52.